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Abstract: Studies have shown that adult bone marrow derived stem cells (MSCs) can participate in repair of myocardial 
injury in adult hearts, as well as in cardiac growth during fetal development in utero. Yet, no studies have evaluated the 
role of MSCs with respect to normal growth or tissue repair in immature hearts after birth. The present study examines 
whether MSCs may participate in the myocardial growth and injury in the post-natal immature hearts. MSCs were isolated 
from adult Lewis rats and labeled with Lac-Z gene using retroviral vectors. These MSCs were injected systemically into 
groups of neonatal (NB=2days-old), immature (B=30days-old) and adult (A=>3months-old) isogeneic Lewis rats. Addi-
tionally, left coronary artery ligation was carried out in subgroups of immature (BL) and adult (AL) rats one week after 
MSCs injection. The hearts were harvested serially from 2-days to 6-weeks, stained with X-Gal for labeled MSCs. Car-
diomyocyte phenotypic expression was evaluated by immunohistological staining for Troponin I-C and Connexin-43. La-
beled MSCs were found to home into the bone marrow in all rats of different developmental stages. They could be re-
cruited from bone marrow into the infarcted site of myocardium only in groups AL and BL. They were also capable of 
differentiating into cardiomyocyte phenotype after myocardial injury. In contrast to that reported in the developing fetus, 
MSCs did not appear to contribute to the growth of non-injured hearts after birth. However, they can be recruited from the 
bone marrow and regenerate damaged myocardium both in the adult and in the immature hearts. 
INTRODUCTION  
  There is considerable evidence indicating that bone mar-
row stromal cells (MSCs) contain multipotent stem cells that 
can be induced to differentiate into cells of various pheno-
types including cardiomyocytes, both in vitro [1] and in vivo 
[2]. Following acute myocardial infarction, experimental and 
early clinical studies reveal that these cells can survive and 
engraft into the peri-infracted myocardium where they can 
differentiate to participate in the repair process [3]. These 
studies had been done so far exclusively in mature animals 
and adult humans with no data on pediatric age group. 
  On the other hand, Liechty KW et al. [4] have shown that 
human MSCs engrafted and demonstrated site-specific dif-
ferentiation after in utero transplantation in a sheep model. 
The donor MSCs could be detected for up to 5 months in 
various fetal tissues, suggesting that the implanted MSCs 
could participate in growth and organogenesis during fetal 
development. However, whether these pluripotent cells could 
participate in the continued growth of myocardium after 
birth remains undetermined.  
  In addition, the extensive experimental work and early 
clinical trials on MSC cell therapy for the treatment of car-
diac patients with congestive heart failure (CHF) have not 
included any pediatric age group despite the fact that CHF 
represents a similarly pertinent problem in infants with con-
genital heart malformation or cardiomyopathy. In this study, 
we attempt to address the question of whether MSCs can 
contribute still in the growth of post-natal immature hearts as 
well as in the repair of injured myocardium in the pediatric 
age group.  
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MATERIALS AND METHODS  
1. Animal Model  
  Syngeneic Lewis rats with different body weight 
(180~200g for adult rats, Immature: 50~70g for immature 
rats, and 6~8g for newborn rats) were obtained from Charles 
River Laboratory (Laprairie Co, Quebec, Canada). These 
inbred rats were used as donors and recipients to simulate the 
autologous implantation of MSCs. All procedures were ap-
proved by the Animal Care Committee of McGill University 
and conformed to the “Guide for the Care and Use of Labo-
ratory Animals” prepared by the Institute of Laboratory 
Animal Resources, National Academy Press (revised 1996), 
and the “Guide to the Care and Use of Experimental Ani-
mals” of the Canadian Council on Animals Care, published 
by the National Academy Press. 
2. Isolation and Culture of MSCs 
  Isolation and primary culture of MSCs from the long 
bone of donor rats were performed as previously described 
using the Caplan’s method [5]. Briefly, the femoral and tibial 
bones were harvested from adult Lewis rats and both ends of 
the long bones were cut away from the diaphyses. The bone 
marrow was flushed out from the bone with complete me-
dium, consisting of Dulbecco’s Modiﬁed Eagle’s Medium 
(DMEM) containing 10% fetal bovine serum and antibiotics: 
100 U/ml penicillin G, 100 mg/mg streptomycin, and 0.25 
mg amphotericin B (Gibco labora¬tories). The marrow plugs 
were then dissociated and the dispersed cells were centri-
fuged and resuspended twice in complete medium. These 
cells were then seeded into tissue culture dishes and cultured 
in an incubator (Forma Scientific, Inc.) with 5% CO2. Cul-
ture medium was replaced every three days and the non-
adherent cells discarded. Following two passages, the at-
tached cells were divided into three new flasks and cultured 
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90% conﬂuence. They were then transfected with reporter 
gene as described below. 
3. Labeling of MSCs  
  After two passages, MSCs were transfected ex vivo, by a 
replication defective retrovirus containing the reporter Lac-Z 
gene that encodes for the bacterial-galactosidase enzyme 
produced by Lac-Z-GP AM12 amphotropic retrovirus pro-
ducer cells [6]. MSCs were cultured with the supernatant 
from the Lac-Z-GP AM12 cells culture flasks with hexadi-
methrine bromide 4ug/ml. Twenty four hours after the last 
transfection, the transfection medium was removed and 
MSCs were maintained in complete medium containing 10% 
fetal bovine serum. Transfection efficiency was monitored in 
a subset of plates with X-gal staining to determine the per-
centage of cells expressing ß-gal activity. Briefly, the cells 
were rinsed with phosphate buffered saline (PBS) and ﬁxed 
with 1% glutaraldehyde at room temperature for 5 minutes. 
After replacing PBS with the staining solution (containing 1 
mg/ml 5-bromo-4-chloro-3-indoyl-b-D-galactoside(X-gal), 
2% dimethylsulfoxide, 20 mM K3Fe(CN)6, 20 mM K4Fe 
(CN)6.3H2O and 2 mM magnesium chloride), cells were in-
cubated at 37°C, pH 7.8 to 8 and protected from light for 16h 
to detect the cells with ß-gal activities. The presence of blue-
labeled cells was then conﬁrmed under inverted microscopy 
(BX-FLA, Olympus, Tokyo, Japan). 
4. Preparation of Cells for Injection  
  Labeled MSCs were cultured with complete medium in 
75 cm
2 tissue culture flasks. On the day of transplantation, 
the cells in each flask were washed with 6 ml of Hank’s Ba-
sic Salt Solution (HBSS), and then trypsinized with 1 ml of 
trypsin-EDTA solution. The detached cell suspension was 
gathered in 2 ml of complete medium and the cell density 
was measured by a hematocytometer. Hence on, cells were 
collected by centrifuged at 1500 rpm for 5 min, and resus-
pended in complete medium without serum at a concentra-
tion of 4x10
7cells/ml. The cell suspensions prepared in the 
tuberculin syringes were placed on ice until implantation. 
5. Implantation of labeled MSCs 
5.1. Intravenous Injection for Implantation of MSCs in 
Adult and Immature Rats 
  Intravenous injection of labeled isogeneic MSCs was 
carried out through the tail vein in the adult (Group A, AL) 
and immature (Group B, BL) recipient rats. The recipient 
rats were placed in a glass canister where 3% isoﬂurane 
(MTC Pharmaceuticals, Cambridge, Ontario, Canada) at 1.5 
l/min was introduced until anesthesia was achieved. General 
anesthesia was maintained by mask inhalation with 1.0% 
isoflurane at the same flow rate. Labeled cell suspension of 
10
5cells/g was injected into the tail vein of adult and imma-
ture rats with a 25-gauge or 28.5-gauge needle respectively.  
5.2. Intraperitoneal Implantation of MSCs in Newborn 
Rats 
  The 2 days-old newborn recipient rats received injection 
of labeled isogeneic MSCs through intraperitoneal route [4] 
because of the lack of venous access in this age group. A 
dose of 4x10
5 cells/g labeled cells were injected into the left 
lower quadrant of the abdomen using a 28.5-gauge needle.  
6. Experimental Groups 
6.1. Marrow Stromal Cell Transplant (n=90) 
  Labeled MSCs were injected systemically into groups of 
neonatal (NB= 2 days-old, n=20), immature (B= 30 days-
old, n=20) and adult (A= >3 months-old, n=40) isogeneic 
Lewis rats.  
  The homing of labeled MSCs within the recipients’ bone 
marrow following systemic injection described above was 
examined at various time points ranging from 2 days to 6 
weeks following the procedure. The bone marrow of the re-
cipient rat was harvested as described earlier, plated and cul-
tured in a similar fashion. When the cells were approxi-
mately 50–60% conﬂuent, they were stained for ß-gal activ-
ity as described above.  
6.2. Coronary Artery Ligation 
  One week after intravenous MSCs injection, 50% of the 
rats from adult (A) or immature group (B) were randomized 
into 2 subgroups (AL group, n=20, and BL group, n=10) and 
underwent coronary artery ligation. Briefly, anesthesia was 
introduced in a glass canister with 3% isoﬂurane at 1.5 l/min, 
and the rat was removed and placed in a restraining device 
after intubated with an intravenous catheter (16-gauge for 
adult rat or 18-gauge for immature rat) and ventilated at a 
tidal volume of 1.5~2.5 ml and a respiratory rate of 85 
breaths/min. The heart was exposed via a left thoracotomy 
incision. The left coronary artery was ligated proximally 
with a 7-0 polypropylene suture. Satisfactory ligation with 
subsequent myocardial infarction was confirmed once an 
ischemic zone and hypokinetic area developed within the left 
ventricle of the heart. The incision was then closed in a ster-
ile fashion and the rats survived until further studied as de-
scribed below. 
7. Histology and Immunohistochemical Studies 
  All rats were electively sacrificed at various time points 
from 2 days to 6 weeks following cell implant, as shown in 
Table1. The hearts were harvested and rinsed with PBS and 
perfusion ﬁxed in 2% paraformaldehyde in PBS. The stain-
ing for ß-galactosidase activity was performed as described 
above, but with the addition of 0.02% Nonidet P-40 and 
0.01% deoxycholate to the staining solution. The gross heart 
specimens were stained over night at 37˚C and pH 7.8. After 
X-gal staining, they were embedded in paraffin and coronal 
sections of 5 m thick were mounted on a set of gelatin 
coated glass slides such that serial sections could be used for 
different stains. A series of sections from each heart speci-
men were stained with hematoxylin and eosin and another 
serial sections from each heart were used for cardiomyocyte-
specific immunohistochemical stainings, namely Connexin-
43 (Zymed Laboratories Inc, San Francisco, CA), and Tro-
ponin I-C (Santa-Cruz Biotechnology Inc, Santa-Cruz, CA). 
Brieﬂy, after de-parafﬁnization, sections were placed in 
boiled citrate buffer (pH 6.0). After blocking in normal se-
rum, sections were treated with the respective monoclonal 
antibodies overnight and with secondary antibodies the fol-
lowing day. Diaminobenzidine (DAB), which produces 
brown color, was then used as a chromogen for light micros-
copy. Counter-staining of sections by hematoxylin was also 
performed. Cells derived from implanted labeled MSCs were 
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9. Statistical Analysis 
  All values are expressed as mean ± standard error of the 
mean (SEM). The unpaired Student’s t test was used to cal-
culate the statistical significance of differences between the 
means of groups. A p-value of less than 0.05 was considered 
to be statistically significant. 
RESULTS 
1. X-Gal Staining of Normal Growing Hearts  
  The MSCs usually become confluent in the culture flask 
after three to four passages of medium changes. At the end 
of Lac-Z gene transfection, the attached MSCs in the flask 
were nearly 100% labeled. The labeled cells stained with X-
Gal solution shows blue nuclei under the inverted micros-
copy (Fig. 1A). 
  The implantation of cells in Groups A, B, and NB had no 
mortality; and all the newborn rats tolerated the intraperito-
neal injections. Two days after implantations, the homing of 
implanted MSCs into the bone marrow of the recipient rats 
were confirmed in all the groups at various time points: 2 
days, 1 week, 3 weeks and 6 weeks.  
  The body weight in group B and group NB had signifi-
cantly grown from 63.1±6.7g to 207.8±7.6g and from 
7.4±1.1g to 50.2±4.0g (p<0.05), respectively (Fig. 2), at 6 
weeks after MSC implantation (Table 2). Yet, we were not 
able to detect any labeled cells in the heart samples taken 
from groups A, B, and NB (Fig.1B) at any time points rang-
ing from 2 days to 6 weeks after implantations when stained 
with X-gal solution.  
2. X-Gal Staining of Hearts after Coronary Ligations 
  In the coronary artery ligation groups (AL and BL), all 
rats survived the surgical procedures throughout the duration 
of the experiments. All the heart samples from one week to 


















Fig. (1). A: Lac-Z labeled MSCs (blue) prior to implantation in culture dish. B: (Group NB) Cross-section of myocardium 3 weeks after 
implantation showed no labeled MSCs in a normal growing heart. Stained with X-gal and counterstained with hematoxylin and eosin. C: 
(Group AL) Cross-section of myocardium 1 week after implantation showed Lac-Z positive cells in the infarcted area. Stained with X-gal 
and counterstained with hematoxylin and eosin. Black arrows show X-gal positively stained cells. D: (Group BL) Cross-section of myocar-
dium 1 week after implantation showed Lac-Z positive cells in the infarcted area. Stained with X-gal and counterstained with hematoxylin 
and eosin. Black arrows show X-gall positively stained cells. E: (Group AL) Cross-section of myocardial scar 6 weeks after coronary liga-
tion showed Troponin I-c positive cells. Brown color in the cytoplasm indicates positive stain. Counterstained with hematoxylin. Black arrow 
showed Lac-Z positive cell. F: (Group BL) Cross-section of myocardial scar 6 weeks after coronary ligation showed Connexin-43 positive 
cells in the peri-infarcted area. Counterstained with hematoxylin. The red arrows show Connexin-43 positive staining. Black arrow shows 
Lac-Z positive stained cells. 30    The Open Cardiovascular Medicine Journal, 2007, Volume 1  Luo et al. 
rior area of the left ventricle that corresponded to the left 
coronary artery distribution. After the heart samples were 
stained with X-gal solution, a consistent blue color could be 
seen in the infarcted myocardium in all LCA-ligated hearts, 
indicating that the labeled MSCs were recruited into the in-











Fig. (2). Body weight changes in groups A, B and NB. Note body 
weights in groups B, NB have significantly increased over 3 weeks 
period. * indicates p<0.05 compared with corresponding weight at 
day 0. 
3. Immunohistochemical Staining of Recipient Hearts 
after Injury 
  In the cross-sections of the injured heart samples taken 
from groups AL and BL, labeled MSCs could be clearly 
identified in all 30 hearts in the region of the scar. The la-
beled cells detected in these infarcted heart samples were 
characterized by undifferentiated appearance with round 
shape and large nucleus to cytoplasm ratio up until 3 weeks 
after implantation (Fig. 1C and Fig. 1D show 1 week sam-
ples). In the 6 weeks specimens, cell shape appeared elon-
gated, resembling the adjacent cardiomyocytes. Immunohis-
tochemical staining showed evidence of cardiomyogenic 
differentiation in some labeled cells with the expression of 
cardiomyocyte-specific Troponin I-C positive staining. The 
main constituent protein for the cardiac gap junctions, Con-
nexin-43, was also detected in the x-gal labeled cells at 6 
weeks specimens only in the coronary ligation groups (Fig. 
1E and Fig. 1F). 
DISCUSSION 
  During cardiac development, the myocyte lineage is de-
rived from the cardiogenic plates, which differentiate into 
contractile cells that rapidly divide and proliferate until the 
perinatal stage [7]. Liechty KW et al. provided evidence that 
there are other cell lineages in the bone marrow which can 
participate in cardiac organogenesis in sheep fetus [4]. Many 
reports have documented the presence of ‘non-hemato-
poietic’ stem cell population in the bone marrow that can 
give rise to stromal supporting elements in both clinical [8] 
and experimental studies [2]. In contrast to that reported in 
the developing fetus [4], the current study was designed to 
evaluate the role of MSCs systemically delivered in the 
adult, immature and newborn rats. Our study suggests that 
MSCs administrated systemically have no significant toxic-
ity to the normal growing individuals, are capable of homing 
to the bone marrow following intravenous [9] or intraperito-
neal infusion. However, we did not find any evidence that 
labeled MSCs contributed to the growth of non-injured 
hearts at different developmental stages from neonates 
through adult ages. This may be related to the different 
mechanism of cardiogenesis during fetal and post-natal de-
velopment. In contrast to the increase in myocardial mass 
prenatally by hyperplasia, the myocardial mass increases 
postnatally with normal growth are largely due to hypertro-
phy of the myocytes [3]. This implies that cell therapy will 
not be effective for promoting cardiac growth in patients 
with congenital heart defects after birth. Whether cell ther-
apy will be able to prevent abnormal cardiac growth in utero 
warrants further investigation. 
  Since implanting bone marrow stem cells into the injured 
ventricle has been shown to improve cardiac function [10-
12], numerous laboratories have focused on studying cellular 
cardiomyoplasty as a means of improving myocardial func-
tion due to heart failure [13-15]. Furthermore, randomized 
controlled clinical trial has been documented that intracoro-
nary injection of autologous MSCs improved left ventricular 
systolic function in patients after acute myocardial infarction 
[9]. Although the mechanism by which stem cells improve 
cardiac function remains unclear, many studies have shown 
evidence that adult bone marrow stromal cells can participate 
in cardiac myogenesis [16], angiogenesis [17], and prevent 
cardiomyocyte apoptosis [12]. In our LCA ligation experi-
ments, the results in the immature hearts are consistent with 
our previous findings in adult rodents [2], i.e. the marrow 
stromal cells residing within the bone marrow are able to be 
recruited, translocated through the blood stream, and mi-
grated into the peri-infarct and infarcted segments of the 
myocardium.  
  One of the most intriguing properties of MSC is their 
ability to home to sites of inflammation or tissue damage. 
Although the steps responsible for this migration have yet to 
Table 1.  The Intervals Between MSCs Injection and Harvesting of Cardiac Specimen 
Group  2 days  1 week  3 weeks  6 weeks  n 
A 4 4 4 8  20 
AL  4 4 4 8  20 
B 2 2 2 4  10 
BL  2 2 2 4  10 
NB  4 4 4 8  20 
A=Adult; AL=Adult and LCA Ligated; B=Immature; BL=Immature and LCA Ligated; NB=New Born. The Immature Heart  The Open Cardiovascular Medicine Journal, 2007, Volume 1    31 
be fully elucidated, data in the literature suggests that it en-
tails a 2-step process whereby stem cells first bind to their 
adhesive complexes around the injury zone, followed by 
local chemotaxis to the site of engraftment [18]. This phe-
nomenon has been demonstrated in various settings includ-
ing infarcted hearts [19], cerebral ischemia [20], and bone 
fractures [21]. In fact, Saito et al. from our laboratory were 
the first to demonstrate that MSCs administered intrave-
nously engraft within the infarcted myocardium, whereas 
those injected in healthy rats, home to the bone marrow [19]. 
In another study, Kraitchman et al. [22] showed the remark-
able specificity with which MSC can home to infarcted re-
gions.  
  SDF-1 and its receptor CXCR4 are required for stem 
cells to home to the bone marrow. Their role in coronary 
artery disease is less clear. Previous studies have shown the 
expression of SDF-1 in atherosclerotic plaques, its upregula-
tion in the heart early after MI as well as the increase in 
neovascularization following its exogenous expression [18]. 
Askari et al. further reinforced the role of SDF-1 in stem cell 
homing in a study whereby cardiac fibroblasts expressing 
SDF-1 were transplanted into the infarcted regions of rat 
hearts [23]. After using granulocyte stimulating factor (G-
CSF) to mobilize stem cells, a significant homing of c-kit 
cells to the injured area as well as an improved cardiac func-
tion was found in treated animals. Orlic and his group have 
also demonstrated the upregulation of MSC homing and dif-
ferentiation with the use of G-CSF [24]. In this study, a 250-
fold increase in the levels of Lin-/c-kit+ cells as well as an 
improvement in the ventricular function were found in rats 
that were pretreated with G-CSF and stem cell factor (SCF). 
A similar finding was obtained when granulocyte-
macrophage stimulating factor (GM-CSF) was used [25]. 
Although the exact mechanism is yet to be understood, 
Harada  et al. recently showed that this G-CSF-mediated 
stem cell mobilization and improvement in cardiac function 
occur through the activation of the Jak/Stat pathway in the 
cardiomyocytes, hence inducing a number of anti-apoptotic 
proteins and angiogenic factors [26]. 
  Other than SDF-1, SCF is also involved in the regulation 
of stem cells migration by binding to its tyrosine kinase re-
ceptor, c-kit, which is expressed on a variety of stem cell 
lines [27]. This is confirmed by further studies showing the 
role of SCF in the induction of the expression of CXCR4 on 
human CD34+ cells resulting in an increase in their migra-
tion in response to SDF-1116. A wide variety of chemokines 
have actually been shown to modulate such migration. How-
ever, the largest response was seen with  and  SDF-1141. 
Furthermore, it is important to realize that although SDF-1 is 
required in stem cell mobilization to the injured site, it is not 
singularly sufficient, hence reflecting the need for additional 
factors. In fact, patients with acute ischemic injury have ele-
vated levels of many factors other than SDF-1 including 
MMP-2, MMP-9, ICAM, and VCAM [28]. 
  Cell-to-cell interactions as well as other environmental 
factors involving a combination of paracrine growth factors 
promote stem cell migration and differentiation. Eghbali-
Webb has recently reviewed the role of cardiac fibroblasts in 
regulating myocardial regeneration by the release of various 
soluble factors within the extracellular matrix such as VEGF, 
FGF, TGF-1, PDGF, and MMPs, highlighting the coordi-
nated cell-to-cell and cell-to-environment interactions [29]. It 
is also possible that the hypoxia following an ischemic insult 
can enhance the expression of some adhesion molecules and 
thus facilitates MSC migration. For instance, the increase in 
MMP-9 level following the use of mobilizing agents such as 
SDF-1, VEGF and G-CSF or after a myocardial infarction, 
leads to an up-regulation of soluble kit, which ultimately 
results in an increase in MSC mobilization and proliferation 
[30, 31]. 
  It is conceivable that the signaling pathways for normal 
growth and tissue injury are very different that may explain 
the different responses of the MSCs following myocardial 
injury and developmental growth. After migrating to the 
injured site, these labeled marrow stromal cells appeared to 
differentiate into various phenotypes, including cardiomyo-
cytes. Since surgical interventions may cause damage to the 
myocardium [24], cellular cardiomyoplasty may be useful 
for repairing the heart muscle after cardiac surgery. Our data 
are consistent with the notion that bone marrow serves as a 
reservoir for potential cardiac precursor cells, which can 
generate cardiomyocytes de novo in the presence of proper 
signal and stimulation. 
  This study has several limitations. First, we have not ex-
amined the issue of “cell fusion”. Although transdifferentia-
tion of MSCs into cardiomyocytes had been reported in vivo 
[4,10,16] and in vitro [32], Murry, C. E.et al. [33] and Ny-
gren, J. M. et al. [34] showed that haematopoietic stem cells 
could adapt the cardiomyocyte phenotype by spontaneous 
fusion with the host cells. Recently, Kajstura, J. et al. [35] 
and others have reported evidence that bone marrow cells 
could indeed differentiate into cardiac cell lineages after in-
farction, independently of cell fusion. Matsuura et al. . [36] 
reported that even after cardiomyocyte fused with surround-
Table 2. 
Group  N  Age  Body weight (g)  Number of MSCs implanted (X10
6) Implantation  Route  Heart* 
A 20  >3M  189.7±8.8  20  IV  - 
AL 20  >3M  185.3±7.8  20  IV  + 
B 10  30D  63.1±6.7  6  IV  - 
BL 10  30D  61.0±6.7  6  IV  + 
NB 20 2D  7.4±1.1  3  IP  - 
A=Adult; AL=Adult and LCA Ligated; B=Immature; BL=Immature and LCA Ligated; NB=New Born; M=Month; D=Days; *: Presence (+) or Absence (-) of labeled MSCs in the 
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ing cells, they could reenter G2-M phase in the cell cycle, 
and maintained their cardiomyocyte phenotype. Wager and 
Weissman [37] proposed that cell fusion-mediated regenera-
tion might be considered one of the physiological mecha-
nisms of repair. These studies suggested that augmented cell 
fusion in the diseased heart may contribute to the mainte-
nance and replenishment of cardiomyocytes, as in the car-
diomyocytic transdifferentiation of implanted cells.  
  Second, the adherent subpopulations of bone marrow 
cells under culture, known as marrow stromal cells (MSCs), 
contain different cell surface markers. In this study, we did 
not fractionate and purify the cells by such specific cell 
markers [38]. However, unlike that of differentiated cells, 
the cell markers expressed by multipotent cells undergoing 
differentiation may change with time and micro-enviro-
nment. Therefore, considerable controversy persists as to the 
usefulness of such markers to identify the differentiating cell 
population contributing to myocardial cell therapy. Other 
limitations of this study include: 1) the lack of quantitative 
study to document the proportion of implanted cells which 
survived and differentiated, and 2) no attempts to investigate 
the functional effects of such therapy in immature hearts. 
Yet, numerous reports had documented the improvement in 
ventricular function associated with anatomical and immu-
nohistochemical findings similar to those observed in our 
study in adult hearts [15, 39, 40].  
  In conclusion, although further studies are needed, our 
findings have shed some lights both on the potential and 
limitations in the use of marrow stromal cell therapy for the 
repair of injured hearts in both adults and immature age 
groups [41], as well as their different response for normal 
growth. 
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